Ventas, Inc.

NYSE:VTR Stock Report

Market Cap: US$24.9b

Ventas Valuation

Is VTR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VTR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VTR ($57.96) is trading below our estimate of fair value ($88.35)

Significantly Below Fair Value: VTR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VTR?

Key metric: As VTR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VTR. This is calculated by dividing VTR's market cap by their current revenue.
What is VTR's PS Ratio?
PS Ratio5.1x
SalesUS$4.80b
Market CapUS$24.91b

Price to Sales Ratio vs Peers

How does VTR's PS Ratio compare to its peers?

The above table shows the PS ratio for VTR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.9x
ARE Alexandria Real Estate Equities
5.5x3.3%US$17.0b
DOC Healthpeak Properties
5.5x5.8%US$14.5b
OHI Omega Healthcare Investors
10.1x0.1%US$10.5b
WELL Welltower
10.3x12.1%US$78.5b
VTR Ventas
5.1x7.5%US$24.9b

Price-To-Sales vs Peers: VTR is good value based on its Price-To-Sales Ratio (5.1x) compared to the peer average (7.3x).

Price to Sales Ratio vs Industry

How does VTR's PS Ratio compare vs other companies in the US Health Care REITs Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DHC Diversified Healthcare Trust
0.4x5.8%US$554.93m
STRW Strawberry Fields REIT
0.7x4.7%US$551.21m
HLTC National Healthcare Properties
0.6xn/aUS$229.77m
GBCS Selectis Health
0.1xn/aUS$3.44m
No more companies available in this PS range
VTR 5.1xIndustry Avg. 5.1xNo. of Companies4PS02.85.68.411.214+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VTR is expensive based on its Price-To-Sales Ratio (5.1x) compared to the US Health Care REITs industry average (5.1x).

Price to Sales Ratio vs Fair Ratio

What is VTR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VTR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.1x
Fair PS Ratio5.6x

Price-To-Sales vs Fair Ratio: VTR is good value based on its Price-To-Sales Ratio (5.1x) compared to the estimated Fair Price-To-Sales Ratio (5.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VTR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$57.96
US$71.26
+23.0%
5.6%US$81.00US$65.00n/a19
Dec ’25US$64.07
US$70.37
+9.8%
7.0%US$79.00US$55.00n/a19
Nov ’25US$64.19
US$67.74
+5.5%
7.6%US$76.00US$55.00n/a19
Oct ’25US$63.89
US$65.26
+2.1%
8.8%US$73.00US$55.00n/a19
Sep ’25US$62.11
US$61.68
-0.7%
7.9%US$70.00US$50.00n/a19
Aug ’25US$55.30
US$56.55
+2.3%
8.9%US$69.00US$49.00n/a19
Jul ’25US$50.88
US$54.56
+7.2%
8.8%US$69.00US$49.00n/a18
Jun ’25US$50.26
US$53.51
+6.5%
9.1%US$69.00US$49.00n/a18
May ’25US$43.81
US$52.42
+19.7%
11.0%US$70.00US$46.00n/a19
Apr ’25US$42.86
US$52.84
+23.3%
11.0%US$70.00US$46.00n/a19
Mar ’25US$44.00
US$53.05
+20.6%
11.1%US$72.00US$46.00n/a20
Feb ’25US$47.23
US$54.30
+15.0%
10.4%US$72.00US$47.00n/a20
Jan ’25US$49.84
US$52.63
+5.6%
11.2%US$72.00US$47.00US$58.8919
Dec ’24US$46.76
US$51.95
+11.1%
10.8%US$72.00US$47.00US$64.0719
Nov ’24US$42.78
US$52.16
+21.9%
16.7%US$80.00US$44.00US$64.1919
Oct ’24US$42.13
US$53.61
+27.3%
15.7%US$80.00US$47.00US$63.8918
Sep ’24US$43.08
US$52.28
+21.4%
9.5%US$68.00US$45.00US$62.1118
Aug ’24US$48.57
US$53.39
+9.9%
9.3%US$68.00US$45.00US$55.3018
Jul ’24US$47.27
US$54.44
+15.2%
14.4%US$80.00US$45.00US$50.8818
Jun ’24US$43.53
US$53.95
+23.9%
13.9%US$80.00US$45.00US$50.2620
May ’24US$47.67
US$53.71
+12.7%
14.1%US$80.00US$45.00US$43.8121
Apr ’24US$43.35
US$55.20
+27.3%
13.6%US$80.00US$45.00US$42.8620
Mar ’24US$47.54
US$55.05
+15.8%
13.8%US$80.00US$45.00US$44.0021
Feb ’24US$51.66
US$54.20
+4.9%
14.3%US$80.00US$45.00US$47.2322
Jan ’24US$45.05
US$52.89
+17.4%
15.8%US$80.00US$45.00US$49.8422

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 05:56
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ventas, Inc. is covered by 43 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jacob KilsteinArgus Research Company
David RodgersBaird
Amanda SweitzerBaird